Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD

Yan Xie(Washington University in St. Louis), Ziyad Al‐Aly(Washington University in St. Louis), Tingting Li(Shihezi University), Hong Xian(UCLouvain Saint-Louis Brussels), Benjamin Bowe(Washington University in St. Louis), Sumitra Balasubramanian(VA St. Louis Health Care System)
Journal of the American Society of Nephrology
March 14, 2016
10.1681/asn.2015121377
Cited by 337

Related Papers

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2018|14k
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet|2017|13.5k
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2018|8.7k
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet|2017|4.9k
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
|The Lancet|2024|4.4k